Related by context. All words. (Click for frequent words.) 83 Genasense R 81 Ganite R 79 Ganite ® 75 Ganite 73 YONDELIS 71 MAGE A3 ASCI 71 EOquin TM 71 phase IIb clinical 71 ELACYT 71 PDX pralatrexate 70 recurrent glioblastoma multiforme 70 sorafenib Nexavar 70 sorafenib tablets 70 docetaxel Taxotere ® 70 Amrubicin 70 forodesine 70 ZACTIMA 70 Virulizin ® 70 Raptiva ® 70 UPLYSO 70 Aflibercept 70 Aplidin 69 Tamibarotene 69 Cloretazine ® 69 R sorafenib tablets 69 ThermoDox R 69 Phase #b/#a clinical 69 oral ridaforolimus 69 acyclovir Lauriad R 69 Allovectin 7 ® 69 metastatic HRPC 69 Seliciclib 69 IMA# 69 Panzem R 68 LEUKINE 68 Dapagliflozin 68 thalidomide Thalomid 68 Fludara ® 68 FOLOTYN ® 68 Pemetrexed 68 Campath ® 68 Golimumab 68 PEGylated Fab fragment 68 Aryplase 68 methylnaltrexone bromide 68 TEMODAL 68 Gemzar ® 68 immunotherapeutic agent 68 BRIM2 68 relapsed leukemia 68 Pirfenidone 68 receptor tyrosine kinase inhibitor 68 metastatic GIST 68 Panzem R NCD 68 IL# PE#QQR 68 Xanafide 68 Troxatyl 68 relapsed multiple myeloma 68 HER2 positive metastatic breast 68 methylnaltrexone 68 Bezielle 68 huC# DM4 68 refractory chronic lymphocytic 68 unique alkylating agent 68 Traficet EN 68 AEG# 68 castration resistant prostate cancer 68 Allovectin 7 68 Vicinium TM 67 Microplasmin 67 Kit CD# positive 67 erlotinib Tarceva ® 67 Genasense 67 mertansine 67 Methylnaltrexone 67 IMiDs ® compound 67 nucleoside analog 67 GW# [003] 67 trabectedin 67 BAY #-# 67 Tarceva TM 67 Bendamustine 67 Velcade bortezomib 67 BR.# 67 Proxinium TM 67 Phase IIIb clinical 67 Combidex 67 Daclizumab 67 OvaRex ® MAb 67 Virulizin R 67 Phase Ib IIa 67 thetreatment 67 relapsing remitting MS RRMS 67 alvespimycin 67 Civacir 67 Onalta ™ 67 Ixempra 67 RhuDex ® 67 Abiraterone acetate 67 Aurexis 67 MyVax R 67 Clolar ® 67 Dacogen injection 67 ruxolitinib 67 oral dual endothelin 67 oropharyngeal candidiasis 67 Afatinib 67 Lubiprostone 67 ganetespib 67 demonstrated antitumor activity 67 Albuferon TM 67 interferon gamma 1b 67 multiple myeloma MM 67 dasatinib Sprycel ® 67 superficial bladder cancer 67 Voreloxin 67 ZOLINZA 67 Eraxis 67 anticancer therapy 67 Ceflatonin R 67 recurrent NSCLC 67 Pivotal Phase III 67 pseudobulbar affect PBA 67 Certolizumab pegol 67 sapacitabine CYC# 67 Advagraf 67 Personalized Immunotherapy 66 sunitinib malate 66 mRCC 66 proteasome inhibitor 66 radiation sensitizer 66 Nexavar ® 66 SinuNase TM 66 Nexavar sorafenib 66 bortezomib Velcade 66 Lucanix R 66 myelodysplastic myeloproliferative diseases 66 Fibrillex TM 66 EGFr expressing metastatic colorectal 66 Zolinza 66 VALSTAR TM 66 amrubicin 66 ixabepilone 66 talactoferrin 66 PI3K/Akt pathway inhibitor 66 OncoVEX GM CSF 66 AVASTIN 66 EGFR expressing mCRC 66 VEGFR2 inhibitor 66 novel oral anticoagulant 66 Ecallantide 66 biologic therapy 66 metastatic hormone refractory 66 CIMZIA ™ 66 Oracea TM 66 HuMax CD4 66 oral prodrug 66 Gemcitabine 66 gefitinib Iressa 66 cetuximab Erbitux 66 terlipressin 66 Peginterferon alfa 2b 66 Mycamine 66 vidofludimus 66 Irinotecan 66 biliary tract cancer 66 SUTENT ® 66 Phase Ib II 66 apaziquone 66 trastuzumab Herceptin R 66 Ceflatonin 66 Pafuramidine 66 CTAP# Capsules 66 essential thrombocythemia ET 66 Urocidin 66 TORISEL 66 Pralatrexate 66 IAP inhibitors 66 PHX# 66 antibody MAb 66 Alocrest 66 abatacept Orencia 66 trastuzumab DM1 T DM1 66 docetaxel Taxotere R 66 INSPIRE Trial Phase III 66 SNT MC# 66 castrate resistant prostate cancer 66 alkylating agent 66 Tolvaptan 66 CIMZIA TM certolizumab pegol 66 TACI Ig 66 Cloretazine 66 vinca alkaloid 66 metastatic RCC 66 PKC# 66 Alemtuzumab 66 metastatic neuroendocrine tumors 66 luliconazole 66 CYT# potent vascular disrupting 66 evaluating tivozanib 66 Surgical resection 66 lintuzumab SGN 66 orally administered inhibitor 66 Neupogen ® 66 anticancer compound 66 IMiDs ® 66 Glufosfamide 66 monoclonal antibody conjugated 66 IRX 2 66 dasatinib Sprycel 66 targeted radiotherapeutic 66 XYOTAX TM 66 fosbretabulin 66 Factor VIIa 66 Uricase PEG 66 depsipeptide 66 oral deforolimus 66 EndoTAG TM -1 66 REBETOL combination therapy 66 COMFORT II 66 relapsed MM 66 Allovectin 7 R 65 MGN# 65 Tavocept 65 cell lymphoma CTCL 65 Vandetanib 65 BRIM3 65 PANVAC VF 65 Evoltra ® 65 systemic anaplastic large 65 Temsirolimus 65 cancer mCRC 65 Initiate Clinical Trial 65 Taxotere docetaxel 65 INTEGRILIN 65 oral iron chelator 65 Silodosin 65 Xeloda ® 65 Degarelix 65 refractory cutaneous T 65 Phase Ib study 65 recurrent metastatic 65 efalizumab 65 metastatic renal cell carcinoma 65 DDP# 65 Pegloticase 65 metastatic CRC 65 Hycamtin 65 TELINTRA 65 dopamine partial agonist 65 axitinib 65 PrevOnco 65 Belimumab 65 intranasal formulation 65 cutaneous T cell 65 refractory indolent non 65 ADVEXIN p# therapy 65 phase IIb trial 65 Talabostat 65 hyaluronidase enzyme 65 enzastaurin 65 recurrent malignant glioma 65 Certican 65 oropharyngeal candidiasis OPC 65 Raptiva R 65 aflibercept VEGF Trap 65 Rebif ® 65 novel VDA molecule 65 EOquin 65 dacarbazine DTIC 65 PDE4 inhibitor 65 cediranib 65 INCB# [001] 65 non nucleoside inhibitor 65 intravesical infusion therapy 65 metastatic castrate resistant 65 FASLODEX 65 galiximab 65 evaluating Xcytrin 65 constipation OIC 65 oxaliplatin Eloxatin 65 advanced metastatic prostate 65 phase IIb III 65 adecatumumab 65 CEQ# 65 Ophena TM 65 Metastatic Melanoma 65 zanolimumab 65 Onco TCS 65 registrational trial 65 CAELYX 65 PEGylated anti 65 bevacizumab Avastin 65 bevacizumab Avastin ® 65 elacytarabine 65 Targretin capsules 65 INCB# [003] 65 relapsed refractory multiple myeloma 65 atypical Hemolytic Uremic Syndrome 65 interferon beta therapy 65 Gleevec resistant 65 Bafetinib 65 PNP inhibitor 65 Combination REOLYSIN R 65 reslizumab 65 G#DT 65 Kepivance 65 Jevtana 65 Enzastaurin 65 recurrent metastatic ovarian cancer 65 Sapacitabine 65 KRN# 65 refractory multiple myeloma 65 humanized anti 65 Vidaza azacitidine 65 Hepatocellular Carcinoma HCC 65 Liprotamase 65 vemurafenib 65 MOZOBIL 65 IMiDs R 65 alfa 2a 65 FOLOTYN 65 Advanced Renal Cell 65 Tanespimycin 65 Archexin 65 Fibrin Pad 65 BEXXAR 65 paclitaxel Taxol ® 65 LymphoStat B TM 65 SAR# [004] 65 opioid induced constipation OIC 65 evaluating picoplatin 65 BRAF inhibitor 65 RhuDex TM 65 Actimmune ® 65 Ridaforolimus 65 octreotide implant 65 Sudhir Agrawal D.Phil 65 rALLy clinical trial 65 Azedra 65 temsirolimus 65 metastatic pancreatic 65 ospemifene 65 treatment naive genotype 65 Cellegesic 65 Cimzia TM 65 Apaziquone 65 small molecule Hedgehog 65 Cx# [002] 65 Eculizumab 65 Arimidex anastrozole 65 PSMA ADC 65 HuMax EGFr 65 rilonacept 65 neratinib 65 LymphoStat B belimumab 65 Cloretazine R VNP#M 65 RAPTIVA 65 sunitinib Sutent 65 Insegia 65 IgG1 monoclonal antibody 65 lapatinib Tykerb 64 BCG refractory 64 Tacrolimus 64 BioNumerik 64 BRAF V# mutation 64 imatinib Gleevec ® 64 Li Fraumeni Syndrome 64 Cancidas 64 hA# 64 refractory metastatic 64 cutaneous T 64 Urocidin TM 64 Chemophase 64 budesonide foam 64 metastatic bladder 64 Bortezomib 64 metastatic castration resistant 64 Teysuno 64 prostate cancer CRPC 64 2 methoxyestradiol 64 selective modulator 64 gemcitabine chemotherapy 64 Mipomersen 64 antimetabolite 64 pain palliation 64 lenalidomide Revlimid R 64 INCB# [002] 64 AMEVIVE 64 class mGluR5 inhibitor 64 RELISTOR ® 64 pegylated liposomal doxorubicin 64 APPRAISE 64 EGFR expressing metastatic colorectal 64 Erlotinib 64 BEMA TM Fentanyl 64 GAMMAGARD 64 advanced metastatic renal 64 Cleviprex TM clevidipine 64 phase III isavuconazole 64 Solazed 64 Sebivo 64 Cloretazine R 64 Phase IIb clinical trials 64 Topotecan 64 lymphoma CTCL 64 Lenocta 64 leading oral taxane 64 neovascular diseases 64 Deferiprone 64 Entecavir 64 lorvotuzumab mertansine 64 Copegus ribavirin 64 dexanabinol 64 ™ pralatrexate injection 64 ACZ# 64 tramiprosate Alzhemed TM 64 Simulect 64 Doxil ® 64 Perifosine 64 HGS# 64 cetuximab Erbitux R 64 Gleevec Glivec 64 estramustine 64 thymalfasin 64 R lenalidomide 64 Bevacizumab 64 Onalta 64 Xeloda capecitabine 64 rindopepimut 64 Tocilizumab 64 KRAS status 64 Carfilzomib 64 HGS ETR1 64 chronic ITP patients 64 MGd 64 Cethromycin 64 PEG SN# 64 vinorelbine tartrate 64 YONDELIS R 64 HGS ETR2 64 PGL# 64 CDK cyclin dependent 64 multi kinase inhibitor 64 kidney urologic 64 metastatic colorectal 64 Genasense ® oblimersen 64 Octreolin 64 Aplidin R 64 gastrointestinal stromal tumors GIST 64 relapsed SCLC 64 inhaled AAT 64 systemic RNAi therapeutic 64 #D#C# 64 lexidronam injection 64 investigational humanized monoclonal antibody 64 Fingolimod 64 anti angiogenic therapy 64 Ophena 64 LE DT 64 ORENCIA R 64 Hormone Refractory Prostate Cancer 64 BARACLUDE R 64 ALVESCO R 64 adalimumab Humira 64 severe hypercholesterolemia 64 unresectable liver cancer 64 including eniluracil ADH 64 Edoxaban 64 Telavancin 64 BLP# Liposome Vaccine 64 Clevudine 64 Aviptadil 64 humanised monoclonal antibody 64 SPRYCEL ® 64 SUTENT 64 induced macular edema 64 Omacetaxine 64 Ofatumumab 64 levocetirizine 64 Annamycin 64 BENLYSTA ® 64 omega interferon 64 PROCHYMAL 64 SUCCEED trial 64 CR# vcMMAE 64 Pathway Inhibitor 64 Besivance 64 Somatuline Depot 64 CRMD# 64 molecular imaging radiopharmaceutical 64 hypereosinophilic syndrome 64 topical antifungal 64 docetaxel chemotherapy 64 class anticancer quinolone 64 adult chronic ITP 64 GTC recombinant human 64 palliative radiotherapy 64 cinacalcet 64 MabCampath 64 Fast Track Status 64 Plicera 64 metastatic gastric 64 Everolimus 64 registrational 64 thymosin alpha 1 64 NeuroStar TMS Therapy 64 Safinamide 64 autologous cellular immunotherapy 64 ulimorelin 64 Proellex TM 64 catheter occlusion 64 Onalta TM 64 Zavesca R 64 targeting CD# 64 investigational monoclonal antibody 64 Patients Treated With 64 Gefitinib 64 MORAb 64 BCG refractory carcinoma 64 Hedgehog Pathway Inhibitor 64 unresectable tumors 64 Xcellerated T Cells 64 JOULFERON 64 nucleotide analogue 64 gemcitabine carboplatin 64 elotuzumab 64 Modrenal R 64 POSIDUR TM 64 OMP #R# 64 VALSTAR 64 Sprycel dasatinib 64 Iluvien ® 64 paclitaxel Taxol R 64 Vitaxin 64 PORxin TM platforms 64 immunomodulatory therapy 64 HCD# [002] 64 Adjuvant Treatment 64 Mimpara 64 lumiliximab 64 Dasatinib 64 MPS IVA 64 huN# DM1 64 HQK 64 BYETTA ® 64 Dabigatran 64 Xelox 64 personalized cellular immunotherapy 64 ongoing Phase 1b 64 MOVIPREP R 64 anthracyclines taxanes 64 posaconazole 64 novel therapeutic antibodies 64 Fodosine 64 HuMax TAC 64 DCVax ® Brain 64 severe gastroparesis 64 PROVENGE ® 64 Temodar ® 64 Taxotere ® 64 Motesanib 64 Tesetaxel 64 ToGA 64 HCV SPRINT 64 papillary renal cell carcinoma 64 TELCYTA 64 recurrent glioblastoma 63 pharmacokinetic PK study 63 benign prostatic hypertrophy BPH 63 FUSILEV enhances 63 HRPC 63 TNF Tumor Necrosis Factor 63 Tezampanel 63 Gliadel Wafer 63 GSK '# 63 Intravenous CP 63 Natalizumab 63 Hodgkin lymphoma HL 63 daptomycin 63 MYCAMINE 63 TLK# 63 Bevacizumab Avastin 63 CLARITY study 63 Moxifloxacin 63 JAK2 inhibitor 63 Erbitux cetuximab 63 Argatroban 63 chemotherapy cisplatin 63 Immunotherapeutic 63 Ambrisentan 63 CINTREDEKIN BESUDOTOX 63 investigational immunotherapy 63 alvimopan 63 Zorbtive TM 63 Navelbine ® 63 aflibercept 63 tolevamer 63 smoldering multiple myeloma 63 lymphoid malignancies 63 Polyphenon ® E 63 refractory acute myeloid 63 TREANDA 63 refractory metastatic colorectal cancer 63 hypoxia activated prodrug 63 tigecycline 63 highly purified pasteurized 63 Thalomid ® 63 PRTX 63 tremelimumab 63 Orphan Drug status 63 FIRMAGON 63 Arimoclomol 63 ANYARA 63 gastrointestinal stromal tumors 63 Romiplostim 63 Boceprevir 63 Marketing Authorisation Application 63 pitavastatin 63 cinacalcet HCl 63 oral antiviral 63 vismodegib 63 nucleoside reverse transcriptase inhibitor 63 advanced hepatocellular carcinoma 63 Cutaneous T 63 assessing T DM1 63 Phase III Pivotal 63 AzaSite Xtra 63 eniluracil 63 Tibotec Therapeutics division 63 carcinoma HCC 63 INC# 63 dacarbazine 63 Panzem 63 Oxaliplatin 63 Zavesca r 63 AP# [003] 63 interferon alfa 2b 63 Proleukin 63 pralatrexate 63 radezolid 63 EGS# 63 ORENCIA ® 63 treat chronic sinusitis 63 stage IIIB 63 PrevOnco ™ 63 diabetic neuropathic pain 63 candidemia 63 Zybrestat 63 acute HAE attacks 63 candidate XP# 63 Naive Patients 63 TheraCIM 63 hepatocellular carcinoma HCC 63 TYZEKA 63 Epratuzumab 63 Arzerra ofatumumab 63 AA amyloidosis 63 Prestara 63 acetonide FA 63 Curaxin CBLC# 63 Hsp# Inhibitor 63 OncoVEX 63 CCR5 antagonist 63 oral picoplatin 63 REPLAGAL 63 post herpetic neuralgia PHN 63 Belinostat 63 CCR5 mAb 63 hepatocellular cancer 63 investigational pan BCR 63 ACTEMRA TM 63 ROTATEQ 63 PD LID 63 Manja Bouman CEO 63 SERMs 63 IRESSA 63 dirucotide MBP# 63 Solazed TM 63 overactive bladder syndrome 63 IV Busulfex 63 ezogabine 63 ancrod 63 silodosin 63 KIACTA ™ 63 GRN# 63 CCX# B 63 Leukine ® 63 Cloretazine VNP#M 63 p# biomarker 63 VNP#M 63 Xcytrin R 63 Mepact 63 ThermoDox ® 63 pediatric acute lymphoblastic 63 JAK inhibitor 63 PROSTVAC ® 63 cilengitide 63 Omnitarg 63 esophageal candidiasis 63 sipuleucel T 63 Azacitidine 63 metastatic malignant 63 Advexin 63 BRILINTA 63 Guanilib 63 EDEMA3 63 Meets Primary Endpoint 63 Phase 2b Clinical Trial 63 systemic ALCL 63 candidates Azedra TM 63 ONCASPAR 63 Aptivus ® 63 tumors GIST 63 CANCIDAS 63 ZEVALIN ® 63 DORIBAX 63 EFAPROXYN 63 EndoTAGTM 1 63 TYKERB 63 deforolimus 63 aripiprazole Abilify 63 miconazole MBT 63 TroVax ® 63 invasive candidiasis 63 ONGLYZA ™ 63 RELOVAIR ™ 63 Canvaxin 63 Genz # 63 OPAXIO 63 sJIA 63 MEK Inhibitor 63 small molecule thrombopoietin 63 phase IIa clinical 63 bile duct tumor 63 NOXAFIL 63 gastrointestinal stromal tumor GIST 63 CDP# 63 hormone agonist 63 liposomal formulation 63 PREZISTA r 63 pegylated interferon alfa 2a 63 Cimzia R 63 BiTE antibody 63 malignant pleural mesothelioma 63 Onconase 63 DCVax R 63 nilotinib Tasigna 63 VAPRISOL 63 Laquinimod 63 hepatitis C HCV 63 NAVISTAR R 63 IV acetaminophen 63 rasagiline tablets 63 PROSTVAC TM 63 XL# anticancer compounds 63 beta 1a 63 Dalbavancin 63 Nimotuzumab 63 ridaforolimus 63 ZADAXIN 63 investigational mTOR inhibitor 63 stage IIIb IV 63 hypervascular tumors 63 Ceflatonin ® 63 Advaxis Phase 63 DOXIL 63 Tyrima 63 systemically administered 63 AFRS TM 63 FOR FURTHER INFORMATION ABOUT 63 Darinaparsin 63 Proquin XR 63 gemcitabine Gemzar 63 glufosfamide 63 PROVENGE sipuleucel T 63 treatment naïve genotype 63 romidepsin 63 PROMACTA 63 dosage regimens 63 DPX Survivac 63 bendamustine 63 HepaGam B 63 RECOTHROM R 63 DEXILANT 63 Ocrelizumab 63 AAG geldanamycin analog 63 investigational therapies 63 toenail onychomycosis 63 Metastatic Colorectal Cancer 63 FavId 63 fluoropyrimidine 63 prostate cancer HRPC 63 Romidepsin 63 Tracleer r 63 trastuzumab Herceptin ® 63 sorafenib Nexavar R 63 5 fluorouracil leucovorin 63 Fludara 63 TOCOSOL Camptothecin 63 previously untreated follicular 63 low dose cytarabine 63 CIMZIA TM 63 OMAPRO ™ 63 sapropterin dihydrochloride 63 BCR ABL inhibitor 63 Vorinostat 63 Anturol TM 63 miconazole Lauriad ® 63 WX UK1 63 orBec 63 Pradefovir 63 subcutaneous formulation 63 MAXY alpha 63 Pyridorin 63 Neulasta ® 63 etanercept Enbrel 63 allogeneic HSCT 63 Hedgehog pathway inhibitor 63 malignant ascites 63 metaglidasen 63 Trofex 63 Rilonacept 63 OMNARIS HFA 63 recombinant interferon 63 Dacetuzumab 63 Zemiva TM 63 MERREM 63 trial evaluating PRX# 63 CD# antibody [001] 63 pan HDAC inhibitor 63 ATL# [002] 63 goserelin 63 BiovaxID TM 63 GVAX ® 63 Elagolix 63 K ras mutations 63 Dementia Related Psychosis 63 ara C 63 histamine dihydrochloride 63 glatiramer 62 efaproxiral 62 recurrent GBM 62 EDEMA4 62 Brentuximab Vedotin SGN 62 bortezomib Velcade R 62 entinostat 62 LEP ETU 62 fostamatinib 62 Pertuzumab 62 Increlex R 62 CA9 SCAN 62 metastatic renal 62 allogeneic bone marrow 62 Nilotinib 62 dose escalation clinical 62 docetaxel Taxotere 62 randomized controlled Phase 62 potent triglyceride lowering 62 pancreatic neuroendocrine tumors 62 Completes Patient Enrollment 62 Orally administered 62 AzaSite Plus 62 nilotinib Tasigna ® 62 Rituxan rituximab 62 radiolabeled TM# 62 Lenalidomide 62 Crohn disease CD 62 relapsing multiple sclerosis 62 Raptiva r 62 neuropathy sparing 62 Orphan Status 62 vapreotide acetate 62 Yondelis ® 62 carcinoid syndrome 62 standard chemotherapy regimen 62 PEG interferon 62 TRISENOX 62 Phase 2b clinical 62 ABILIFY ® 62 ZADAXIN ® 62 antibody MT# 62 post operative ileus 62 IMGN# 62 tafamidis 62 ASONEP 62 relapsed ovarian cancer 62 Myocet 62 Vidofludimus 62 Oral Fingolimod 62 Orphan Drug Status 62 ATL# [001] 62 P#X# antagonist 62 personalized immunotherapy 62 topical gel formulation 62 generation Hsp# inhibitor 62 NP2 Enkephalin 62 mGluR5 NAM 62 intravenous methylnaltrexone 62 INTEGRILIN R 62 neurogenic bladder 62 cMET 62 LBH# 62 Mitoxantrone 62 candidate deforolimus 62 chimeric monoclonal antibody 62 AQ4N 62 MEK inhibitors 62 Phase IIb Trial 62 OMP designation 62 hormone LHRH antagonist 62 small molecule chemotherapeutic 62 Elvitegravir 62 compound INCB# 62 carboplatin paclitaxel 62 atrial fibrillation budiodarone ATI 62 IMC A# 62 gallium nitrate injection 62 Pfizer Sutent 62 Amgen Neulasta R 62 Phase III Clinical Trial 62 pertuzumab 62 superficial basal cell carcinoma 62 tubulin inhibitor 62 Hepatocellular Carcinoma 62 Renal Cell Carcinoma RCC 62 Zarnestra 62 Granted Orphan Drug 62 panobinostat 62 sunitinib Sutent ® 62 Junovan 62 refractory CTCL 62 StemEx 62 Phase IIIb study 62 talabostat 62 GLPG# 62 CDK inhibitor 62 nucleoside analogue 62 situ CIS 62 CA4P 62 anti inflammatory NSAID 62 satraplatin Phase 62 R bendamustine hydrochloride 62 Brilique 62 Quinamed 62 Kamada AAT 62 imatinib Gleevec 62 oxymorphone ER 62 drug ISA# 62 de novo kidney transplant 62 Paraplatin ® 62 oral JAK#/JAK# inhibitor 62 synthetic retinoid 62 evaluating T DM1 62 HepaGam B TM 62 Pazopanib 62 OvaRex R 62 BrachySil TM 62 AA Amyloidosis 62 tanespimycin 62 histone deacetylase HDAC inhibitor 62 sorafenib Nexavar ® 62 Maraviroc 62 AZILECT ® 62 mifamurtide 62 myeloproliferative disorders 62 Bayer Nexavar 62 plus dexamethasone 62 Pegasys ® 62 pouchitis 62 Adjuvant chemotherapy 62 rituximab refractory 62 TORISEL TM 62 Canvaxin TM 62 Azilect ® 62 polycythemia vera PV 62 Antitumor Activity 62 Tasimelteon 62 Alvesco R 62 GVAX R 62 bendamustine HCl 62 BCR ABL inhibitors 62 systemic fungal infections 62 non resectable 62 SIR Spheres 62 Æterna Zentaris 62 SinuNase ™ 62 THALOMID 62 Nexavar prescribing 62 fallopian tube carcinoma 62 refractory Hodgkin lymphoma 62 Prostate AdenoCarcinoma Treatment 62 Pharmacokinetics PK 62 Vivaglobin 62 mitogen activated ERK kinase 62 valtorcitabine 62 Entereg R 62 Atypical Hemolytic Uremic Syndrome 62 Kuvan R